NovoCure Limited
NVCR
$12.43
$0.524.37%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 630.16M | 621.71M | 605.22M | 577.74M | 549.96M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 630.16M | 621.71M | 605.22M | 577.74M | 549.96M |
| Cost of Revenue | 147.88M | 141.06M | 136.23M | 135.53M | 132.25M |
| Gross Profit | 482.28M | 480.65M | 468.99M | 442.21M | 417.72M |
| SG&A Expenses | 441.41M | 434.72M | 428.89M | 383.73M | 383.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 801.99M | 787.60M | 774.76M | 729.93M | 728.31M |
| Operating Income | -171.83M | -165.89M | -169.54M | -152.19M | -178.35M |
| Income Before Tax | -142.07M | -129.82M | -131.16M | -114.49M | -141.13M |
| Income Tax Expenses | 28.89M | 34.37M | 37.47M | 35.29M | 27.57M |
| Earnings from Continuing Operations | -170.95 | -164.19 | -168.63 | -149.78 | -168.70 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -170.95M | -164.19M | -168.63M | -149.78M | -168.70M |
| EBIT | -171.83M | -165.89M | -169.54M | -152.19M | -178.35M |
| EBITDA | -160.87M | -155.51M | -159.68M | -142.61M | -168.42M |
| EPS Basic | -1.56 | -1.51 | -1.56 | -1.39 | -1.57 |
| Normalized Basic EPS | -0.96 | -0.90 | -0.92 | -0.79 | -0.95 |
| EPS Diluted | -1.56 | -1.51 | -1.56 | -1.39 | -1.57 |
| Normalized Diluted EPS | -0.96 | -0.90 | -0.92 | -0.79 | -0.95 |
| Average Basic Shares Outstanding | 438.58M | 434.70M | 431.69M | 430.20M | 428.72M |
| Average Diluted Shares Outstanding | 438.58M | 434.70M | 431.69M | 430.20M | 428.72M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |